The Expensive Kidney Test You Might Not Need: New Study Reveals The Urinary Protein-Creatinine Ratio (UPCR) Is Just as Accurate as the Premium Albumin Test
Forget the expensive albumin test. New data shows protein-creatinine ratio predicts kidney risks just as well.
Let's be honest. Managing a chronic condition like chronic kidney disease is a full-time job. Between the appointments, the diet, and the meds, the last thing you want to worry about is whether you spent too much on a lab test. A new study published in the Journal of the American Medical Association might offer some relief for your wallet. Researchers led by Ashish Verma from the Boston University Chobanian & Avedisian School of Medicine looked at a massive dataset to see if two very common tests are actually different enough to matter. You can check out the full details on the journal's website here.
The team analyzed data from 3742 participants in the Chronic Renal Insufficiency Cohort Study. They tracked these patients for a median of 15.0 years. That is a long time to stare at a wall. During that period, they looked at three critical outcomes for the participants. Kidney failure happened to 32.3 percent of the group. Another 39.6 percent saw their condition progress. And 31.5 percent dealt with a composite of heart issues. To find out more about the background of this research, visit the nephrology news section.
The core question was whether the Urinary Albumin-Creatinine Ratio (UACR) and the Urinary Protein-Creatinine Ratio (UPCR) predicted these outcomes differently. The numbers suggest they do not. Log-transformed versions of both ratios were strongly correlated. The risk of kidney failure was 3.00 times higher for one and 2.75 times higher for the other per standard deviation. But when it came to accuracy, the difference was tiny. The five-year time-dependent area under the curve was 0.894 for UACR and 0.899 for UPCR. A difference of less than 0.01 is basically a rounding error in medicine.
This means you do not have to stress if your doctor suggests the protein test because the albumin one is out of stock or budget. The authors write that the UPCR can be used without meaningful loss of information. They emphasize that both markers are valuable. But if money is tight, you do not need to worry about missing out on prognostic value by choosing the cheaper option. You can read the peer-reviewed findings here to see exactly how the researchers reached this conclusion.
Science reporting like this relies on good editing to make sure the complicated medical jargon is digestible. The piece was put together by copy editor Gaby Clark and writer Robert Egan. Gaby has a background in higher education and English, while Robert brings a unique perspective from his math biology background. They work to ensure stories on science are trustworthy and accurate. For more about how these stories come together, you can check out their profiles.
First reported by Medical Xpress.
More in Health & Nutrition
- Long-term opioid use fails to alleviate chronic back pain, Northwestern University study suggests
Researchers identified distinct brain activity patterns and molecular markers that may guide future treatments for pain management and opioid tapering.
- Human tau seeds trigger disease-specific shapes in mouse brains, new study finds
Study in Nature shows that injectable human tau aggregates from Alzheimer’s and corticobasal degeneration template their 3D folds onto mouse tau, supporting the prion-like seeding model.
- Menopause Largely Missing from Electronic Health Records Despite Its Health Impact
study of nearly 240,000 women finds only 12% of electronic records include menopause status, even though over half reported being in transition.